Small molecule · Inhibitor of insulin receptor substrate 1 (IRS1), insulin receptor substrate 2 (IRS2) and signal transducer and activator of transcription 3 (STAT3)
Phase 1/2Most advanced trial
1Registered trials
What is NT219?
NT219 is a small molecule that binds and inhibits IRS1, IRS2 and STAT3, preventing STAT3 nuclear translocation and IRS-mediated survival signaling in tumor cells. It is being studied in head and neck squamous cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Drug type
Small molecule
Targets
insulin receptor substrate 1 (IRS1), insulin receptor substrate 2 (IRS2), signal transducer and activator of transcription 3 (STAT3)
Mechanism
Inhibitor of insulin receptor substrate 1 (IRS1), insulin receptor substrate 2 (IRS2) and signal transducer and activator of transcription 3 (STAT3)
Pathways
IRS1/2-mediated signaling, STAT3 nuclear translocation and oncogene expression, apoptosis
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.